Before testing the impact of CPI-613 on a subpopulation of ovarian CSCs, the baseline CD133 and CD117 levels were determined in the five ovarian serous cancer cell lines used in our study. The gene discussed is PROM1; the disease is ovarian serous adenocarcinoma.